-
Mashup Score: 0Prostate Cancer Treatment Revolution: Radiotherapy and Abiraterone in the Spotlight of PEACE-1 - Alberto Bossi - 7 month(s) ago
In a discussion between Alicia Morgans and Alberto Bossi, they delved into the PEACE-1 data. Professor Bossi outlined the European study initiated by himself and Karim Fizazi, focusing on the potential impact of radiotherapy and abiraterone on the prognosis of metastatic prostate cancer patients. Discussing the study’s results, Professor Bossi revealed no overall survival benefit from…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Prostate Cancer Treatment Revolution: Radiotherapy and Abiraterone in the Spotlight of PEACE-1 - Alberto Bossi - 7 month(s) ago
In a discussion between Alicia Morgans and Alberto Bossi, they delved into the PEACE-1 data. Professor Bossi outlined the European study initiated by himself and Karim Fizazi, focusing on the potential impact of radiotherapy and abiraterone on the prognosis of metastatic prostate cancer patients. Discussing the study’s results, Professor Bossi revealed no overall survival benefit from…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#ProstateCancer treatment revolution: radiotherapy and abiraterone in the spotlight of #PEACE1. Join @AlbertoBossial @GustaveRoussy and @CaPsurvivorship @DanaFarber as they discuss the results and significant benefits found in this study > https://t.co/CyDi7BiwRm https://t.co/LbOdYbp7IS
-
-
Mashup Score: 0Prostate Cancer Treatment Revolution: Radiotherapy and Abiraterone in the Spotlight of PEACE-1 - Alberto Bossi - 8 month(s) ago
In a discussion between Alicia Morgans and Alberto Bossi, they delved into the PEACE-1 data. Professor Bossi outlined the European study initiated by himself and Karim Fizazi, focusing on the potential impact of radiotherapy and abiraterone on the prognosis of metastatic prostate cancer patients. Discussing the study’s results, Professor Bossi revealed no overall survival benefit from…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#ProstateCancer treatment revolution: radiotherapy and abiraterone in the spotlight of #PEACE1. Join @AlbertoBossial @GustaveRoussy and @CaPsurvivorship @DanaFarber as they discuss the results and significant benefits found in this study > https://t.co/CyDi7BiwRm https://t.co/8frV97k6nj
-
-
Mashup Score: 1Prostate Cancer Treatment Revolution: Radiotherapy and Abiraterone in the Spotlight of PEACE-1 - Alberto Bossi - 10 month(s) ago
In a discussion between Alicia Morgans and Alberto Bossi, they delved into the PEACE-1 data. Professor Bossi outlined the European study initiated by himself and Karim Fizazi, focusing on the potential impact of radiotherapy and abiraterone on the prognosis of metastatic prostate cancer patients. Discussing the study’s results, Professor Bossi revealed no overall survival benefit from…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#ProstateCancer treatment revolution: radiotherapy and abiraterone in the spotlight of #PEACE1. Join @AlbertoBossial @GustaveRoussy and @CaPsurvivorship @DanaFarber as they discuss the results and significant benefits found in this study > https://t.co/CyDi7BiwRm https://t.co/39wC5tlZF6
-
-
Mashup Score: 0
ASCO 2023 results from the phase III PEACE-1 trial, prostate irradiation in men with de novo low-volume metastatic castrate-sensitive prostate cancer (mCSPC), PEACE consortium, Prostate Cancer Consortium in Europe.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Prostate irradiation in men with de novo, low-volume #mCSPC: Results of #PEACE1, a phase 3 randomized trial with a 2x2 design. Presented by @AlbertoBossial @GustaveRoussy. #ASCO23 written coverage by @RKSayyid > https://t.co/9TKz4pFGSG #ProstateCancer @ASCO https://t.co/ke1rQ2U9Ct
-
-
Mashup Score: 14Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Observation from #ENZAMET ✅ Adding enzalutamide to TS plus docetaxel had the same treatment effect as adding abiraterone (#PEACE1) to darolutamide (#ARASENS) to TS + docetaxel in pts presenting with synchronous mHSPC https://t.co/zj4jsmIhIf https://t.co/KfWLPR8k7O
-
-
Mashup Score: 2
ASCO GU 2023 results from the PEACE-1 trial, de novo metastatic-castration sensitive prostate cancer (mCSPC), abiraterone acetate + prednisone to ADT +/- docetaxel in mCSPC, LATITUDE and STAMPEDE trials.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of abiraterone acetate + prednisone and ADT +/- docetaxel in older pts (≥70 Years), with de novo #mCSPC, compared to younger pts (70 Years): the #PEACE1 trial. Presented by Loic Mourey, MD. @ASCO #GU23 coverage by @zklaassen_md > https://t.co/ClzMhzYCdj https://t.co/pBTS68UsjB
-
-
Mashup Score: 08-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam - 1 year(s) ago
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
8-month PSA outcomes of men with #mCSPC in the #PEACE1 phase 3 trial. Gwenaëlle Gravis Mescam, MD @univamu joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/bFSrgjPKwk https://t.co/AD6kwzVHAu
-
-
Mashup Score: 08-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam - 1 year(s) ago
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
8-month PSA outcomes of men with #mCSPC in the #PEACE1 phase 3 trial. Gwenaëlle Gravis Mescam, MD @univamu joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/bFSrgjPKwk https://t.co/UGbaHkXy6e
-
-
Mashup Score: 08-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam - 1 year(s) ago
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
8-month PSA outcomes of men with #mCSPC in the #PEACE1 phase 3 trial. Gwenaëlle Gravis Mescam, MD @univamu joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/bFSrgjPKwk https://t.co/9KZNfAdtiH
-
#ProstateCancer treatment revolution: radiotherapy and abiraterone in the spotlight of #PEACE1. Join @AlbertoBossial @GustaveRoussy and @CaPsurvivorship @DanaFarber as they discuss the results and significant benefits found in this study > https://t.co/CyDi7BiwRm https://t.co/x2wlqmRztM